RG7795
From WikiMD's WELLNESSPEDIA
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| RG7795 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 1174920-78-5 |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B.[1] It is an orally-available prodrug of isatoribine,[2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.[3] Its active metabolite is an [agonist]] of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.[2]
References[edit]
- ↑ RG 7795(link). {{{website}}}. AdisInsight.
- ↑ 2.0 2.1 "Tickling the TLR7 to cure viral hepatitis.".Journal of Translational Medicine.14 May 2014;12
- 129.doi:10.1186/1479-5876-12-129.PMID:24884741.PMC:4039542.
- ↑ , Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration Full text, Genetic Engineering News, August 3, 2016,
RG7795[edit]
-
RG-7795
-
Isatoribine
